journal article·2024-06

Bioenergetic Metabolism Modulatory Peptide Hydrogel for Cardiac Protection and Repair After Myocardial Infarction

Yushan Zhang, Yu Gao, Jingrong Wang, Rui Gao, Qi Su, Ju Zhang, Liqin Jiang, Chuangnian Zhang, Pingsheng Huang, Weiwei Wang, Zujian Feng

Advanced Functional Materials· Volume 34· Issue 24
Publisher page

Abstract

Abstract Myocardial infarction (MI) remains a major threat to human health due to the limited energy supply, disordered cell metabolism, massive cardiomyocyte death, and restricted regeneration. Although currently available therapies may relieve myocardial damage, restoring the dysregulated energy metabolism to normal levels has not yet been achieved. MOTS‐c has recently been identified as a regulator of biological metabolism to combat aging; however, its role in reprogramming cardiac metabolism remains to be elucidated. Here, MOTS‐c is chemically conjugated to self‐assembling Q11 peptide to fabricate an injectable hydrogel (MQgel) aimed to improve mitochondria function and cardiomyocyte metabolism post‐MI. It is observed that MQgel effectively protects mitochondria from oxidative damage and normalized cardiomyocyte metabolism, including glucose uptake, glycolysis, and the tricarboxylic acid (TCA) cycle, thereby inhibiting cardiomyocyte death and enhancing cardiomyocyte activity. In a rat MI model, intramyocardial injection of MQgel successfully minimizes the infarct area and fibrosis, promotes angiogenesis, suppresses myocardial hypertrophy, and improves cardiomyocyte survival and metabolic enzyme activity, all of which collaboratively attenuate the maladaptive cardiac remodeling and boost cardiac function and tissue repair. The findings suggest that the self‐assembled mitochondria metabolism‐regulatory peptide hydrogel effectively treats MI, and cellular bioenergy modulation provides a new therapeutic approach for tissue repair after injury.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Tissue Engineering and Regenerative Medicine · Peptidase Inhibition and Analysis · Electrospun Nanofibers in Biomedical Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Advanced Medical Materials and Devices Institute of Biomedical Engineering Chinese Academy of Medical Sciences and Peking Union Medical College Tianjin 300192 China

Key Laboratory of Innovative Cardiovascular Devices Chinese Academy of Medical Sciences Beijing 100037 China

Funding

Natural Science Foundation of Tianjin Municipality · Fundamental Research Funds for the Central Universities · National Natural Science Foundation of China

References (50)

Show source-provided references
1. 10.1038/s41392-022-00925-z10.1038/s41392-022-00925-z ↗
2. 10.1038/s41467-022-35437-510.1038/s41467-022-35437-5 ↗
3. 10.1126/sciadv.abd674010.1126/sciadv.abd6740 ↗
4. 10.1002/advs.20210540810.1002/advs.202105408 ↗
5. 10.1038/s41467-023-37832-y10.1038/s41467-023-37832-y ↗
6. 10.1016/j.biomaterials.2021.12085510.1016/j.biomaterials.2021.120855 ↗
7. 10.1016/j.bioactmat.2022.06.00110.1016/j.bioactmat.2022.06.001 ↗
8. 10.1038/nm.365310.1038/nm.3653 ↗
9. 10.1016/j.cej.2020.12742310.1016/j.cej.2020.127423 ↗
10. 10.1093/cvr/cvy06710.1093/cvr/cvy067 ↗
11. 10.7150/thno.6014310.7150/thno.60143 ↗
12. 10.1038/s41569-018-0074-010.1038/s41569-018-0074-0 ↗
13. 10.1016/j.ebiom.2020.10288410.1016/j.ebiom.2020.102884 ↗
14. 10.1016/j.freeradbiomed.2021.02.04110.1016/j.freeradbiomed.2021.02.041 ↗
15. 10.1038/s41401-020-0476-510.1038/s41401-020-0476-5 ↗
16. 10.1111/jcmm.1518010.1111/jcmm.15180 ↗
17. 10.1161/JAHA.119.01267310.1161/JAHA.119.012673 ↗
18. 10.1038/s12276-019-0355-710.1038/s12276-019-0355-7 ↗
19. 10.1016/j.yjmcc.2016.09.00110.1016/j.yjmcc.2016.09.001 ↗
20. 10.1161/CIRCHEARTFAILURE.114.00115110.1161/CIRCHEARTFAILURE.114.001151 ↗
21. 10.1002/adfm.20200645410.1002/adfm.202006454 ↗
22. 10.1021/acsnano.3c0145210.1021/acsnano.3c01452 ↗
23. 10.1016/j.actbio.2016.11.06810.1016/j.actbio.2016.11.068 ↗
24. 10.1038/s41467-019-12748-810.1038/s41467-019-12748-8 ↗
25. 10.1016/j.actbio.2016.10.01310.1016/j.actbio.2016.10.013 ↗
26. 10.1016/j.yexcr.2020.11205610.1016/j.yexcr.2020.112056 ↗
27. 10.1016/j.freeradbiomed.2016.05.01510.1016/j.freeradbiomed.2016.05.015 ↗
28. 10.1016/j.cmet.2015.02.00910.1016/j.cmet.2015.02.009 ↗
29. 10.1039/C6TB02969H10.1039/C6TB02969H ↗
30. 10.1016/j.jconrel.2021.05.02310.1016/j.jconrel.2021.05.023 ↗
31. 10.1161/CIRCULATIONAHA.107.72742010.1161/CIRCULATIONAHA.107.727420 ↗
32. 10.1002/adhm.20230002910.1002/adhm.202300029 ↗
33. 10.1016/j.biomaterials.2022.12165610.1016/j.biomaterials.2022.121656 ↗
34. 10.1016/j.biomaterials.2020.12021010.1016/j.biomaterials.2020.120210 ↗
35. 10.1161/CIRCHEARTFAILURE.115.00220610.1161/CIRCHEARTFAILURE.115.002206 ↗
36. 10.1016/j.cmet.2015.12.00910.1016/j.cmet.2015.12.009 ↗
37. 10.1038/s41419-019-1734-710.1038/s41419-019-1734-7 ↗
38. 10.1002/adhm.20220099010.1002/adhm.202200990 ↗
39. 10.1161/CIRCULATIONAHA.120.04995210.1161/CIRCULATIONAHA.120.049952 ↗
40. 10.1093/cvr/cvaa14810.1093/cvr/cvaa148 ↗
41. 10.1093/cvr/cvv27910.1093/cvr/cvv279 ↗
42. 10.1172/JCI8443110.1172/JCI84431 ↗
43. 10.1002/adhm.20220167110.1002/adhm.202201671 ↗
44. 10.1016/j.cmet.2018.06.00810.1016/j.cmet.2018.06.008 ↗
45. 10.1021/acs.nanolett.0c0278110.1021/acs.nanolett.0c02781 ↗
46. 10.7150/thno.3580310.7150/thno.35803 ↗
47. 10.1039/D3SM01057K10.1039/D3SM01057K ↗
48. 10.1016/j.jcmg.2010.10.00810.1016/j.jcmg.2010.10.008 ↗
49. 10.1016/j.biomaterials.2015.04.04610.1016/j.biomaterials.2015.04.046 ↗
50. 10.1016/j.actbio.2016.05.03910.1016/j.actbio.2016.05.039 ↗